| Schedule of segment reporting information |
The information in the following tables is derived directly from each reportable segment’s financial reporting.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, 2015 |
Diagnostics |
Therapeutics |
Corporate |
Total |
Lymphoseek sales revenue: |
|
|
|
|
United States1
|
$ |
1,963,273 |
|
$ |
— |
|
$ |
— |
|
$ |
1,963,273 |
|
International |
275 |
|
— |
|
— |
|
275 |
|
Lymphoseek license revenue |
250,000 |
|
— |
|
— |
|
250,000 |
|
Grant and other revenue |
654,360 |
|
— |
|
— |
|
654,360 |
|
Total revenue |
2,867,908 |
|
— |
|
— |
|
2,867,908 |
|
Cost of goods sold |
332,730 |
|
— |
|
— |
|
332,730 |
|
Research and development expenses |
2,120,336 |
|
176,738 |
|
— |
|
2,297,074 |
|
|
Selling, general and administrative expenses,
excluding depreciation and amortization2
|
1,529,042 |
|
64,018 |
|
2,341,838 |
|
3,934,898 |
|
Depreciation and amortization |
72,289 |
|
— |
|
77,058 |
|
149,347 |
|
Loss from operations3
|
(1,151,043 |
) |
(240,756 |
) |
(2,418,896 |
) |
(3,810,695 |
) |
|
Other income (expense), excluding
equity in the loss of R-NAV, LLC4
|
— |
|
— |
|
(5,874,019 |
) |
(5,874,019 |
) |
Equity in the loss of R-NAV, LLC |
— |
|
— |
|
(6,205 |
) |
(6,205 |
) |
Net loss |
(1,151,043 |
) |
(240,756 |
) |
(8,299,120 |
) |
(9,690,919 |
) |
Total assets, net of depreciation and amortization: |
|
|
|
|
|
United States |
4,035,926 |
|
— |
|
17,690,779 |
|
21,726,705 |
|
International |
470,033 |
|
— |
|
1,851 |
|
471,884 |
|
Capital expenditures |
25,492 |
|
— |
|
2,126 |
|
27,618 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, 2015 |
Diagnostics |
Therapeutics |
Corporate |
Total |
Lymphoseek sales revenue: |
|
|
|
|
United States1
|
$ |
3,793,920 |
|
$ |
— |
|
$ |
— |
|
$ |
3,793,920 |
|
International |
5,050 |
|
— |
|
— |
|
5,050 |
|
Lymphoseek license revenue |
333,333 |
|
— |
|
— |
|
333,333 |
|
Grant and other revenue |
844,061 |
|
— |
|
— |
|
844,061 |
|
Total revenue |
4,976,364 |
|
— |
|
— |
|
4,976,364 |
|
Cost of goods sold |
781,787 |
|
— |
|
— |
|
781,787 |
|
Research and development expenses |
6,015,610 |
|
262,752 |
|
— |
|
6,278,362 |
|
|
Selling, general and administrative expenses,
excluding depreciation and amortization2
|
3,571,217 |
|
78,384 |
|
5,665,304 |
|
9,314,905 |
|
Depreciation and amortization |
144,397 |
|
— |
|
154,742 |
|
299,139 |
|
Loss from operations3
|
(5,465,571 |
) |
(341,136 |
) |
(5,820,045 |
) |
(11,626,752 |
) |
|
Other income (expense), excluding
equity in the loss of R-NAV, LLC4
|
— |
|
— |
|
(5,086,960 |
) |
(5,086,960 |
) |
Equity in the loss of R-NAV, LLC |
— |
|
— |
|
(268,432 |
) |
(268,432 |
) |
Net loss |
(5,465,571 |
) |
(341,136 |
) |
(11,175,437 |
) |
(16,982,144 |
) |
Total assets, net of depreciation and amortization: |
|
|
|
|
United States |
4,035,926 |
|
— |
|
17,690,779 |
|
21,726,705 |
|
International |
470,033 |
|
— |
|
1,851 |
|
471,884 |
|
Capital expenditures |
25,492 |
|
— |
|
2,126 |
|
27,618 |
|
1 All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies.
2 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments.
3 Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
4 Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.
|